Current Clinical Trials
All Clinical Trials
Hematology
Name of this trial: SAPHAIRE
What type of cancer is this for? Warm Autoimmune Hemolytic Anemia (wAIHA)
Who is this trial for? Patients with warm autoimmune hemolytic anemia who have failed at 1 least 1 prior line of treatment. Failure, meaning a drop in hemoglobin of ≥ 1g/dL and an increase in LDH levels. Patients must have received a minimum of 4 weeks of other immunosuppression therapy, or 3 months of immunosuppression therapy.
What biomarkers are involved? None
What is the National Clinical Trial #? NCT05786573
Brief summary of this trial: Phase 3, randomized, double-blinded, placebo controlled trial, looking at effect of weekly subcutaneous injection of obexelimab and selected quality of life assessments.
Need to know: Patients will be allowed to continue up to 2 prior failed therapies throughout the 24-week study period, in addition to study treatment.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065
Leukemia
Name of this trial: ASC2ESCALATE
What type of cancer is this for? CML (Chronic Myeloid Leukemia)
Who is this trial for? Men and women with chronic myeloid leukemia without T315I mutation who have had one prior ATP-binding site TKI (tyrosine kinase inhibitors) that was stopped because it stopped working or the side effects were too hard to take.
What biomarkers are involved? You must NOT have a T315I mutation.
National Clinical Trial # NCT05384587
Brief summary of this trial: This trial is looking to see how effective Asciminib is in patients with CML, as a second drug that they get to treat it.
Need to know: You need to have tried a TKI (tyrosine kinase inhibitor) like Sprycel or Tarceva and then stopped taking it.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065
Biliary Tract
NAME: PanTumor3- Biliary Tree
What type of cancer is this for: Liver, gallbladder, bile ducts
Phase: II
Who is this trial for: Men and women who have cancer in their biliary tract: liver and/or gallbladder and/or bile ducts that has spread to other parts of the body and cannot be taken out.
What biomarkers are involved? Your cancer cells must be positive for Trop2
What is National Clinical Trial #? NCT05489211
Brief summary of trial: This trial is looking to see how well the study drug (Dato-DXd) works on biliary tract cancers that have spread, as well as how safe the drug is.
Need to know: You need to have tried either Gemzar & Carboplatin OR Gemzar & Cisplatin in the past.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Breast
Name of Trial: Tropion 04
What type of cancer is this for? Triple Negative Breast Cancer
Phase of this trial? 3
Who is the trial for? Men or women diagnosed with Stage II or III bilateral or unilateral primary invasive breast cancer. who have not yet had surgery or plan to not have surgery.
What biomarkers/mutations are necessary? HER2-, HR – or HR low
What is the National Clinical Trials info? NCT06112379
Brief summary of Trial: The is a randomized study looking at effectiveness and safety of pre-surgical Dato-DXd plus durvalumab, followed by post-surgical durvalumab with or without chemotherapy. Compared with pre-surgical pembrolizumab plus chemo, followed by post-surgical pembrolizumab with or without chemotherapy, in previously untreated participants.
Need to know: Stage II or III localized breast cancer patients who require pre-surgical treatment, and is newly diagnosed with breast cancer that is triple negative, or low hormone receptor negative.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of Trial? Capitello-292
Phase of this trial? Phase 3
Who is this trial for? Men and Women with hormone positive, HER2 negative breast cancer that is locally advanced and inoperable.
What biomarkers are involved? None
Clinical Trial # NCT04862663
Brief Summary of Trial: This is a randomized 1:1 trial that is looking at new drug Capivasertib in combination with anti-hormone drug and a CDK4/6 inhibitor (oral drug), vs. anti-hormone drug plus CDK4/6 inhibitor. The study is looking for which works best.
Need to Know: Must have relapsed on or within 12 months of completing first line endocrine therapy (such as Tamoxifen, or another AI), maximum of 1 line of chemotherapy in advanced disease setting.
Where is this trial available? Cancer and Hematology Centers and other sites nationwide, please click on link for other locations,
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of the trial? INAVO 121
What type of cancer is this for? Metastatic HER+/HER2- Breast Cancer
Phase of trial? Phase 3
Who is this trial for? Men and post-menopausal women, who have locally recurrent or metastatic breast cancer, who have only had 2 previous lines of treatment in the metastatic setting.
What biomarkers are involved? HR+, HER2-, PIK3CA
What is the National Clinical Trial #? NCT05646862
Summary of the trial: A randomized study Evaluating the Efficacy and Safety of Inavolisib (Oral drug) Plus Fulvestrant (Hormone injection) Compared With Alpelisib (Oral drug) Plus Fulvestrant (Hormone injection).
Need to know information: Can only have had 2 prior treatments in metastatic setting, must have PIK3CA mutation which will be tested with tissue from previous biopsy, cannot have Type 1 diabetes, or Type 2 diabetes that requires treatment.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: ELAINE 3
What type of cancer is this for? BREAST
Phase of this trial: Phase III
Who is this trial for? Men and Women with Breast Cancer that has spread to other parts of the body.
What biomarkers are involved? You must have estrogen receptor positive, HER2 negative Breast Cancer with an ESR1 Mutation
What is National Clinical Trial #? NCT05696626
Brief summary of trial: This trial compares how effective and safe the combination of Lasofoxifene and Abemaciclib is, compared to the combination of Fulvestrant and Abemaciclib. Lasofoxifene and Abemaciclib are both pills, and Fulvestrant is an injection.
Need to know: You must have tried Ribociclib or palbociclib-based treatment before.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name: SERENA 6
What type of cancer is this for? BREAST
Phase: III
Who is this trial for? Men and women with Breast Cancer that has spread to other parts of the body.
What biomarkers are involved? You must be hormone receptor (HR) positive, HER2 negative and have a positive ESR1 mutation
What is National Clinical Trial #? NCT04964934
Brief summary of trial: This trial looks to see how well AZD9833 (the drug that is being studied) plus palbociclib or abemaciclib works compared to either anastrozole or letrozole plus palbociclib or abemaciclib.
Need to know: You must have tried either anastrozole or letrozole plus a CDK4/6 inhibitor (Abemaciclib, Palbociclib or Ribociclib)
Where is this trial available?: The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial? BEGONIA
What type of cancer is this for? BREAST
Phase of this trial? Phase II
Who is this trial for? Men and Women with breast Cancer that has spread to other parts of the body.
What biomarkers are involved? You must have estrogen receptor negative, progesterone receptor negative and HER2 negative breast cancer.
What is the National Clinical Trial #? NCT03742102
Brief summary of trial: This trial is looking to see how safe and well-tolerated Durvalumab and datopotamab deruxtecan are.
Need to know: You can have had treatment for your breast cancer before it spread, but now that it has spread, this has to be the first treatment you receive for it.
Where is this trial available?: The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: GILEAD ASCENT-05
What type of cancer is this for? BREAST Cancer Triple Negative
Phase of this trial: Phase III
Who is this trial for? Men and Women with Breast Cancer early stage not cured with chemotherapy and surgery.
What biomarkers are involved? You must have estrogen receptor negative, progesterone receptor negative, and HER2 negative Breast Cancer
What is National Clinical Trial #? NCT05633654
Brief summary of trial: This trial compares how effective and safe the combination of Sacituzumab Govitecan and Pembrolizumab is, compared to treatment of physician’s choice in patients with triple negative breast cancer who have residual invasive disease after surgery and neoadjuvant therapy.
Need to know: Must have had neoadjuvant treatment and surgery for breast surgery with residual disease.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Colorectal
Name of this trial: CODEBREAK 301
What type of cancer is this for? COLON
Phase of this trial? Phase III
Who is this trial for? Men and women with colon cancer that has spread to other parts of the body.
What biomarkers are involved? Your cancer must have a KRAS P.G12C mutation.
What is the National Clinical Trial# NCT04303780
Brief summary of trial: This trial is randomized 1:1 to either Sotorarsib+Panitumumab+FOLFIRI (standard chemo regimen) vs. standard of care chemotherapy regimens FOLFOX or FOLFIRI +/- Avastin. The study is investigating which of these treatment plans shows longer overall survival and progression-free survival in metastatic colon cancer patients.
Need to know: You may have had treatment for your colon cancer before it spread, but now that it has spread, this has to be the first treatment you receive for it.
Where is this trial available?: The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: CARDIFF-004
What type of cancer is this for? COLORECTAL cancer
Phase of this trial? Phase II
Who is this trial for? Men and Women with colorectal cancer that has spread but they have never had treatment for their disease.
What biomarkers are involved? Your cancer must have a KRAS or NRAS mutation.
What is the National Clinical Trial# NCT06106308
Brief summary of trial: This trial looks at how well two different doses of the study drug (onvansertib) work when combined with two different chemotherapy plans.
Need to know: You may have had treatment for your colorectal cancer before it spread, but now that it has spread, this has to be the first treatment you receive for it.
Where is this trial available?: The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Esophageal
NAME: GEMINI GASTRIC
What type of cancer is this for? Stomach and where the stomach and esophagus join together
Phase: II
Who is this trial for: Men and women who have stomach cancer, or cancer where the stomach and esophagus meet, that cannot be removed or has spread to other parts of the body
What biomarkers are involved? Your tumor CANNOT be positive for HER-2.
What is National Clinical Trial #? NCT05702229
Brief summary of trial: This trial is looking to see how well two new drugs (MEDI5752 and AZD2936) work with chemotherapy plans that already exist.
Need to know: This must be the first treatment you receive since finding out your cancer has spread.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Biliary Tract Cancer Clinical Trials
Biliary Tract
NAME: PanTumor3- Biliary Tree
What type of cancer is this for: Liver, gallbladder, bile ducts
Phase: II
Who is this trial for: Men and women who have cancer in their biliary tract: liver and/or gallbladder and/or bile ducts that has spread to other parts of the body and cannot be taken out.
What biomarkers are involved? Your cancer cells must be positive for Trop2
What is National Clinical Trial #? NCT05489211
Brief summary of trial: This trial is looking to see how well the study drug (Dato-DXd) works on biliary tract cancers that have spread, as well as how safe the drug is.
Need to know: You need to have tried either Gemzar & Carboplatin OR Gemzar & Cisplatin in the past.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Bladder Cancer Clinical Trials
Breast Cancer Clinical Trials
Colorectal Cancer Clinical Trials
Colorectal
Name of this trial: CODEBREAK 301
What type of cancer is this for? COLON
Phase of this trial? Phase III
Who is this trial for? Men and women with colon cancer that has spread to other parts of the body.
What biomarkers are involved? Your cancer must have a KRAS P.G12C mutation.
What is the National Clinical Trial# NCT04303780
Brief summary of trial: This trial is randomized 1:1 to either Sotorarsib+Panitumumab+FOLFIRI (standard chemo regimen) vs. standard of care chemotherapy regimens FOLFOX or FOLFIRI +/- Avastin. The study is investigating which of these treatment plans shows longer overall survival and progression-free survival in metastatic colon cancer patients.
Need to know: You may have had treatment for your colon cancer before it spread, but now that it has spread, this has to be the first treatment you receive for it.
Where is this trial available?: The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: CARDIFF-004
What type of cancer is this for? COLORECTAL cancer
Phase of this trial? Phase II
Who is this trial for? Men and Women with colorectal cancer that has spread but they have never had treatment for their disease.
What biomarkers are involved? Your cancer must have a KRAS or NRAS mutation.
What is the National Clinical Trial# NCT06106308
Brief summary of trial: This trial looks at how well two different doses of the study drug (onvansertib) work when combined with two different chemotherapy plans.
Need to know: You may have had treatment for your colorectal cancer before it spread, but now that it has spread, this has to be the first treatment you receive for it.
Where is this trial available?: The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Esophageal Cancer Clinical Trials
Esophageal
NAME: GEMINI GASTRIC
What type of cancer is this for? Stomach and where the stomach and esophagus join together
Phase: II
Who is this trial for: Men and women who have stomach cancer, or cancer where the stomach and esophagus meet, that cannot be removed or has spread to other parts of the body
What biomarkers are involved? Your tumor CANNOT be positive for HER-2.
What is National Clinical Trial #? NCT05702229
Brief summary of trial: This trial is looking to see how well two new drugs (MEDI5752 and AZD2936) work with chemotherapy plans that already exist.
Need to know: This must be the first treatment you receive since finding out your cancer has spread.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Gallbladder Cancer Clinical Trials
Gallbladder
NAME: PanTumor3- Biliary Tree
What type of cancer is this for: Liver, gallbladder, bile ducts
Phase: II
Who is this trial for: Men and women who have cancer in their biliary tract: liver and/or gallbladder and/or bile ducts that has spread to other parts of the body and cannot be taken out.
What biomarkers are involved? Your cancer cells must be positive for Trop2
What is National Clinical Trial #? NCT05489211
Brief summary of trial: This trial is looking to see how well the study drug (Dato-DXd) works on biliary tract cancers that have spread, as well as how safe the drug is.
Need to know: You need to have tried either Gemzar & Carboplatin OR Gemzar & Cisplatin in the past.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Gastric Cancer Clinical Trials
Gastric
NAME: GEMINI GASTRIC
What type of cancer is this for? Stomach and where the stomach and esophagus join together
Phase: II
Who is this trial for: Men and women who have stomach cancer, or cancer where the stomach and esophagus meet, that cannot be removed or has spread to other parts of the body
What biomarkers are involved? Your tumor CANNOT be positive for HER-2.
What is National Clinical Trial #? NCT05702229
Brief summary of trial: This trial is looking to see how well two new drugs (MEDI5752 and AZD2936) work with chemotherapy plans that already exist.
Need to know: This must be the first treatment you receive since finding out your cancer has spread.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Kidney Cancer Clinical Trials
Kidney
Leukemia Clinical Trials
Leukemia
Name of this trial: ASC2ESCALATE
What type of cancer is this for? CML (Chronic Myeloid Leukemia)
Who is this trial for? Men and women with chronic myeloid leukemia without T315I mutation who have had one prior ATP-binding site TKI (tyrosine kinase inhibitors) that was stopped because it stopped working or the side effects were too hard to take.
What biomarkers are involved? You must NOT have a T315I mutation.
National Clinical Trial # NCT05384587
Brief summary of this trial: This trial is looking to see how effective Asciminib is in patients with CML, as a second drug that they get to treat it.
Need to know: You need to have tried a TKI (tyrosine kinase inhibitor) like Sprycel or Tarceva and then stopped taking it.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065
Liver Cancer Clinical Trials
Liver
NAME: PanTumor3- Biliary Tree
What type of cancer is this for: Liver, gallbladder, bile ducts
Phase: II
Who is this trial for: Men and women who have cancer in their biliary tract: liver and/or gallbladder and/or bile ducts that has spread to other parts of the body and cannot be taken out.
What biomarkers are involved? Your cancer cells must be positive for Trop2
What is National Clinical Trial #? NCT05489211
Brief summary of trial: This trial is looking to see how well the study drug (Dato-DXd) works on biliary tract cancers that have spread, as well as how safe the drug is.
Need to know: You need to have tried either Gemzar & Carboplatin OR Gemzar & Cisplatin in the past.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
NAME: IMBRAVE 152
What type of cancer is this for? HEPATOCELLULAR (LIVER) cancer
Phase of this trial? Phase III
Who is this trial for? Men and women with liver cancer that has spread either locally or to other parts of the body.
What biomarkers are involved? None
What is the National Clinical Trial #? NCT05904886
Brief summary of trial: This study will evaluate how well the study drug (tiragolumab) works and how safe it is, compared to an existing known therapy.
Need to know: You may have had treatment for your liver cancer before it spread, but now that it has spread, this has to be the first treatment you receive for it.
Where is this trial available?: The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Lung Cancer Clinical Trials
Lung
Name: GENMAB
What type of cancer is this for? Non-small-cell lung cancer
Phase: II
Who is this trial for? Men and women who have non-small-cell lung cancer that has spread to other parts of their body.
What biomarkers are involved? Your tumor must have PD-L1 expression in greater than 1% of your tumor cells.
What is National Clinical Trial #? NCT05117242
Brief summary of trial: This study compares how well their new drug works (shrinks the tumors) by itself vs. giving it with “pembrolizumab”.
Need to know: You need to have had the standard treatment (chemo) and an “immune checkpoint inhibitor” as prior treatment.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of Trial: JUSTAR-001
What type of cancer is this trial for? Limited Stage, Small-cell Lung cancer
Who is this trial for? Patients with limited stage small cell lung cancer who have not progressed after initial chemotherapy/radiation.
What biomarkers are involved? None
National Clinical Trial # NCT06095583
Brief Summary of trial: Study is looking to compare and evaluate efficacy of new drug Tifcemalimab combined with Toripalimab vs. PLACEBO after consolidation chemotherapy for small cell lung cancer. This is a blinded study, so patients will not know whether they are receiving investigational drug or not.
Need to know information: Must not have received prior immunotherapy for small-cell lung cancer, and cannot have extensive stage/metastatic small cell lung cancer.
Where is this trial available? The Cancer and Hematology Centers and other sites nationwide, please click on link above for other potential sites.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name: Pacific-9
What kind of cancer is this for? Non-small cell lung cancer
Phase: III
Who is this trial for? Men and women with locally advanced (Stage III) non-small cell lung cancer that cannot be removed by a doctor.
What biomarkers are involved? PD-L1, EGFR and ALK
What is National Clinical Trial #? NCT05221840
Brief summary of trial: This study is looking to prove that durvalumab and oleclumab work better than durvalumab and a placebo (harmless medication) do.
Need to know: You must have had a chemo plan that included either Cisplatin or Carboplatin, along with radiation at the same time you were getting chemotherapy. Your disease cannot have grown any bigger since chemo and radiation finished.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of Trial? Sunray-01
What type of Cancer is this for? Non-small cell Lung cancer
What biomarkers are involved? KRAS G12C-mutation, PD-L1 expression
National Clinical Trials # NCT06119581
Brief Summary of trial: Locally advanced, or metastatic non-small cell lung cancer, never treated. This is first line treatment with study drug LY3537982 (pill) or placebo, in combination with immunotherapy and chemotherapy.
Need to know information: No prior treatment for lung cancer. We will do mutation testing to determine eligibility from prior biopsy/blood sample. This is a blinded trial with study drug LY3537982/placebo. All patients will receive the oral drug but the provider nor research team will know whether you are getting drug/placebo.
Where is this trial available? The Cancer and Hematology Centers and other sites nationwide, please click on link above for other potential sites.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Lymphoma Clinical Trials
Lymphoma
Name of the trial? Abbvie M23-362
What type of cancer is this for? Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (previously Gr 1-3a)
Phase of trial? Phase 2
Who is this trial for? Previously treated Follicular Lymphoma, Now B-cell lymphoma. Relapsed or refractory Follicular Lymphoma.
What biomarkers are involved? None
What is the National Clinical Trial #? NCT05451810
Summary of the trial: A study to evaluate adverse events of subcutaneous (injection) Epcoritamab, administered in the outpatient setting.
Need to know information: For relapsed/refractory Diffuse Large B-cell Lymphoma, previously treated with at least 1 line of systemic chemotherapy. Can have either failed prior transplant or was overage for transplant. For Relapsed/Refractory Follicular Lymphoma, previously treated with at least 2 lines of therapy, including 1 monoclonal antibody, previously treated with chemotherapy or lenalidomide. Have progressed on the last prior line of therapy. This trial is open at all Cancer and Hematology sites, however, the first 2 cycles must be done at our main location in downtown Grand Rapids.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
NAME: ACERTA ESCALADE
What kind of cancer is this for? Diffuse Large B-Cell lymphoma.
Phase: III
Who is this trial for? Men and women who are younger than or equal to 75 years old with lymphoma that has never been treated before.
What biomarkers are involved? None
What is National Clinical Trial #? NCT04529772
Brief summary of trial: This trial is looking to see if the study drug (acalabrutinib) added to RCHOP (chemo plan) works better than RCHOP and a harmless drug.
Need to know: You must be younger or equal to 75 years old and your cancer cell type must be non-germinal center B-cell lymphoma.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of this trial: Olympia-2, R1979-ONC-2075
What type of cancer is this trial for? Untreated Follicular Lymphoma
Trial Phase: 3
Who is this trial for? This trial is for newly diagnosed or untreated patients with Follicular Lymphoma.
What biomarkers are required for eligibility? CD20+ Follicular Lymphoma
National Clinical Trial #? NCT06097364
Brief Summary of the trial: This trial is looking at how well a new drug Odronextamb combined with Chemotherapy works, and the safety of drug compared to Rituximab (already approved treatment)and Chemotherapy for follicular lymphoma.
Need to know: Must have not had any previous treatment for follicular lymphoma.
Where is this trial available? The Cancer and Hematology Centers and other various sites across the country. Please click on link above for more information.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Melanoma Clinical Trials
Melanoma
NAME: IDE196-009
What kind of cancer is this for? Uveal melanoma
Phase: II
Who is this trial for? Men and women with primary uveal melanoma that requires either removal of the eye or radiation therapy.
What biomarkers are involved? None
What is National Clinical Trial #? NCT05907954
Brief summary of trial: This study is looking to see how people feel while they are taking the study drug, as well as how safe it is.
Need to know: The study drug is a pill, and you will have many eye exams during the trial.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
NAME: IDE196-002
What kind of cancer is this for? Metastatic Uveal melanoma
Phase: II/III
Who is this trial for? Men and women with uveal melanoma that has spread to other parts of their body.
What biomarkers are involved? None
What is National Clinical Trial #? NCT05987332
Brief summary of trial: This study is looking at how well the study drug (IDE196) plus crizotinib works, as well as how you feel when taking it.
Need to know: Your serotype must be HLA-A*02:01 negative.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of Trial: V940 (Merck)
What type of cancer is this for? Melanoma
Phase of this trial: Phase 3
Who is this trial for? Men and Women with high-risk stage II-IV melanoma.
What biomarkers are involved? none
What is National Clinical Trial #? NCT05933577
Brief summary of trial: A Phase 3 blinded clinical trial looking at a combination of Immunotherapy (pembrolizumab) plus V940 vaccine/placebo, in patients with surgically resected melanoma.
Need to know information: Individuals who have had surgical resection of Stage II-IV melanoma of the skin, who have not had any previous treatment beyond surgery.
Where is this trial available? The Cancer and Hematology Centers at Lemmon-Holton and other sites nationwide, click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Multiple Myeloma Clinical Trials
Multiple Myeloma
Name: COBRA
What kind of cancer is this for: Multiple Myeloma
Phase: III
Who is this trial for? Men and women who have just found out that they have multiple myeloma
What biomarkers are involved? None
What is National Clinical Trial#? NCT03729804
Brief summary of trial: This trial is looking at which treatment plan works better at 12 and 24 months after starting.
Need to know: Both transplant and non-transplant candidates are eligible. Transplant candidates must agree at the time of consent to defer transplant to the end of study treatment.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Myelodysplastic Syndrome Clinical Trials
Multiple Myeloma
Name: COBRA
What kind of cancer is this for: Multiple Myeloma
Phase: III
Who is this trial for? Men and women who have just found out that they have multiple myeloma
What biomarkers are involved? None
What is National Clinical Trial#? NCT03729804
Brief summary of trial: This trial is looking at which treatment plan works better at 12 and 24 months after starting.
Need to know: Both transplant and non-transplant candidates are eligible. Transplant candidates must agree at the time of consent to defer transplant to the end of study treatment.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Myelofibrosis Clinical Trials
Myelofibrosis
Name of Trial: Karyopharm XPORT-MF-034
What type of Cancer is this for? Myelofibrosis (Blood cancer)
Phase: 3
Who is this trial for? Patients with myelofibrosis or post-essential thrombocythemia (ET) or postpolycythemia-vera (PV) myelofibrosis.
What biomarkers involved? None
What is the National Clinical Trial #? NCT04562389
Brief Summary: Purpose of this study is to evaluate the drug Selinexor in combination with Ruxolitinib vs. Placebo plus Ruxolitinib. This is a double-blinded randomized clinical trial with 2:1 ratio.
Need to know: This trial is for patients who have not yet had any treatment for their blood cancer.
Where is this trial available? This trial is available at The Cancer and Hematology at Lemmon-Holton Cancer Pavilion, and at The Cancer and Hematology Centers in Muskegon. This trial is also available at other sites nationwide.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Pancreatic Cancer Clinical Trials
Pancreas
Prostate Cancer Clinical Trials
Prostate
Name of this trial: MK-5684-004
What type of cancer is this for? PROSTATE cancer
Phase of this trial? Phase III
Who is this trial for? Men with prostate cancer that has spread while taking a next generation hormonal agent.
What biomarkers are involved? None
What is the National Clinical Trial# NCT06136650
Brief summary of trial: This trial is comparing the study drug (MK-5684) to two other drugs, looking to prove that the study drug helps men live longer. It is randomized 1:1.
Need to know: Your prostate cancer must be castration resistant (cancer that continues to grow even when the testosterone levels are at or below the castrate level) and your disease has to have progressed when you were on or after you received a Next Generation Hormonal Agent such as enzalutamide, abiraterone acetate, apalutamide, and darolutamide.
Where is this trial available?: The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name: CAPITELLO-281
What type of cancer is this for? Prostate
Phase: III
Who is this trial for? Men who have hormone sensitive prostate cancer (testosterone can be stopped or blocked to help prevent cancer growth) that has spread to other parts of the body.
What is National Clinical Trial #? : NCT04493853
Brief summary of trial: This trial is looking to see how well capivasertib and abiraterone work compared to a harmless medicine and abiraterone.
Need to know: Your tumor tissue must be PTEN negative. (PTEN stands for Phosphatase and TENsin homolog deleted on chromosome 10)
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Name of Trial: Evopar-Prostate
What type of cancer is this trial for? Patients with hormone resistant, metastatic castration-sensitive prostate cancer
What biomarkers are involved? None
National Clinical Trial # NCT06120491
Brief Summary of the trial: Patients with metastatic hormone-resistant and non-hormone resistant metastatic castration-sensitive prostate cancer, will receive physician’s choice of new hormonal agent in combination with either new drug AZD5305 vs. PLACEBO. This is a double-blinded study, which means neither patient nor provider will know whether patients are receiving AZD5305 drug or placebo.
Need to know information: These drugs are pills, not IV, and you may get placebo in combination with hormone agent.
Where is this trial available? The Cancer and Hematology Centers and other sites nationwide, please click on link above for other potential sites.
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
NAME: PanTumor 3- PROSTATE
What type of cancer is this for? Prostate
Phase: II
Who is this trial for? Men with advanced prostate cancer that may have spread to other parts of your body.
What biomarkers are involved? None
What is National Clinical Trial #? NCT05489211
Brief summary of trial: This trial is looking to see what drug combination works better to treat your prostate cancer.
Need to know: Your prostate cancer must be “castration-resistant”, which means that your cancer continues to grow even when your testosterone level is very low.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
Registry Trials
Registry Trial
NAME: EXACT- Registry trial
What kind of cancer is this for? All cancer types
Phase: N/A
Who is this trial for? Men and women who either have a diagnosis of cancer, a clinical suspicion of cancer, a diagnosis of recurrent cancer or a clinical suspicion of recurrent cancer.
What biomarkers are involved? Multiple
What is National Clinical Trial #?
Brief summary of trial: This study is looking at tissue and blood samples from cancer patients, to study the biomarkers they find in the blood or tissue to help and come up with future therapies.
Need to know: There are no medications in this trial, you would need to give a blood or tissue sample for the sponsor to evaluate.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com
NAME: Oracle- Registry trial
What kind of cancer is this for? All types
Phase: N/A
Who is this trial for? The primary study population will include participants with invasive bladder, ureteral, or renal pelvis carcinoma, non-small cell lung cancer, and breast cancer. Exploratory cohorts include participants with cutaneous melanoma, esophageal carcinoma, gastroesophageal junction carcinoma, gastric adenocarcinoma, pancreatic adenocarcinoma, squamous cell carcinoma of the head and neck, epithelial ovarian/Fallopian tube carcinoma, endometrial cancer, renal cell carcinoma (RCC), and rectal adenocarcinoma.
What biomarkers are involved? None
What is National Clinical Trial #? NCT05059444
Brief summary of trial: This study wants to test an assay that they have developed, which could help detect recurrence in people with certain tumors.
Need to know: There are no medications on this trial, just blood draws and tissue samples are needed.
Where is this trial available? The Cancer & Hematology Centers
For more information, please call 616-975-3065 or email clinicaltrials@chcwm.com